Biogen Inc (BIIB)

288.44
1.40 0.49
NASDAQ : Health Care
Prev Close 287.04
Open 286.83
Day Low/High 286.08 / 288.77
52 Wk Low/High 223.02 / 338.51
Volume 1.29M
Avg Volume 1.90M
Exchange NASDAQ
Shares Outstanding 219.12M
Market Cap 62.96B
EPS 15.40
P/E Ratio 20.29
Div & Yield N.A. (N.A)

Latest News

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Roger Ailes, Biogen Shake-Up and Other Notable CEO Departures of 2016

Roger Ailes, Biogen Shake-Up and Other Notable CEO Departures of 2016

Biogen's announcement that CEO George Scangos would step down as head of the biotech company marks the latest company to see its chief leave the perch this year.

Chart of the Day: Celgene

Celgene is showing relative strength on a weak market day.

Dow Snaps Seven-Day Record Streak on Flood of Earnings

Dow Snaps Seven-Day Record Streak on Flood of Earnings

The Dow Jones Industrial Average's record-breaking seven-day streak came to a quiet end on Thursday as a mix of earnings came in weaker than expected.

Stocks at Session Lows as Winning Streak Is Threatened

Stocks at Session Lows as Winning Streak Is Threatened

Stocks are at session lows by mid-afternoon Thursday as a flood of mixed earnings keeps investors busy.

Evercore's Schoenebaum Explains Biotech Boom on CNBC

Evercore's Schoenebaum Explains Biotech Boom on CNBC

While discussing what is driving the biotech sector higher, Evercore's Mark Schoenebaum recommended investing in Biogen (BIIB) stock on CNBC today.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Midday Report: Existing Home Sales at Best Since 2007; U.S. Stocks Mixed

Midday Report: Existing Home Sales at Best Since 2007; U.S. Stocks Mixed

Quarterly reports continued to come in at breakneck speed with some of the key highlights including American Express, eBay, General Motors, Southwest Airlines, and Biogen.

Stocks Waver on Flood of Mixed Earnings From GM to Intel

Stocks Waver on Flood of Mixed Earnings From GM to Intel

Stocks remain narrowly mixed on Thursday as earnings take focus and U.S. existing home sales reach their best level in more than nine years.

Biogen Shares Climb on Earnings Beat, CEO Departure

Biogen Shares Climb on Earnings Beat, CEO Departure

Biogen shares could be on a turnaround trajectory after a year of disappointments.

Biogen (BIIB) Stock Soars on Q2 Earnings, Revenue Beat

Biogen (BIIB) Stock Soars on Q2 Earnings, Revenue Beat

Biogen (BIIB) reported higher-than-expected 2016 second quarter earnings and revenue before the market open.

Morning Movers: GM, JOY, RLYP, BIIB

Morning Movers: GM, JOY, RLYP, BIIB

General Motors crushed Wall Street earnings estimates before the opening bell.

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

The departure of Biogen's CEO could lead to a sale of the biotech company, or a renewed push to boost its own M&A activities.

Biogen (BIIB) Strong In Pre-Market Trading

Biogen (BIIB) Strong In Pre-Market Trading

Trade-Ideas LLC identified Biogen (BIIB) as a pre-market leader candidate

Biogen Reports Second Quarter 2016 Revenues Of $2.9 Billion

Biogen Reports Second Quarter 2016 Revenues Of $2.9 Billion

Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2016 financial results, including: Total revenues of $2.

Http://www.sobi.com (Graphic: Business Wire)

Http://www.sobi.com (Graphic: Business Wire)

Biogen (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) will present updated data on long-term safety and efficacy of the companies' novel extended half-life therapies,...

SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted For Review By European Medicines Agency

SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted For Review By European Medicines Agency

The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira ®1, has been accepted for review by the European Medicines Agency (EMA).

What to Watch This Week: Bank of America, Goldman Sachs, Netflix and Yahoo! Report Earnings

What to Watch This Week: Bank of America, Goldman Sachs, Netflix and Yahoo! Report Earnings

For the week of July 18, the earnings parade continues, with dozens of major companies reporting financial results.

Here's Why Action Alerts PLUS Exited Biogen Today

Here's Why Action Alerts PLUS Exited Biogen Today

The charitable trust sold out of its position in Biogen while also trimming its holdings in Target.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Friday Trades: Exiting and Trimming

We will sell our remaining holdings in Biogen and cut back on Target.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

Video: Explaining Our Downgrades

There have been a few lately.

WhiteWave Rides Another Downgrade

WhiteWave Rides Another Downgrade

The organic food producer was downgraded to 'Hold' by Jefferies.

We're Selling Some Kraft Heinz and Biogen

Now's a good time to trim positions.

We're Downgrading 4 Stocks

Comcast, PepsiCo, Biogen and Target get lower ratings.

Biogen: Quality at a Discount

Biogen: Quality at a Discount

Biotechs now offer some great valuations, and BIIB is prime example.

Action Alerts PLUS Weekly Roundup

We adjusted our holdings this week in four portfolio names, adding to Comcast and Visa but trimming Costco and Walgreens.